Galectin therapeutics inc (GALT)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-3,556

-5,137

-2,784

-2,998

-2,375

-3,050

-2,752

-3,840

-4,258

-2,382

-4,408

-4,508

-4,937

-4,591

-4,526

-5,519

-6,800

-4,671

-5,887

-4,643

-4,826

-3,731

-3,518

-3,429

-5,110

Adjustments to reconcile net loss to net cash flows from operating activities:
Payment of preferred stock dividends

-

-

-

-

395

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of preferred stock dividends

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

-

-

-

0

0

0

1

2

2

2

1

1

2

2

2

2

3

3

2

Stock-based compensation expense

430

414

414

443

412

1,152

663

1,443

1,187

272

230

269

330

478

376

402

1,223

873

793

799

935

799

877

746

1,648

Amortization of right to use lease asset

9

9

8

8

10

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock for services

-

-

-

-

-

1

1

3

7

6

9

4

14

-

-

-

-

-

-

-

-

-

-

-

-

Loss from equity method investment in Galectin Sciences LLC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-10

-53

-67

-270

Non-cash interest expense

22

22

22

21

22

80

87

85

84

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other assets

-173

595

-516

140

137

353

-146

-145

-81

371

-149

-151

-79

379

-186

-186

-129

371

-122

-306

78

443

3

-64

-47

Accounts payable and accrued expenses

-1,449

1,528

-47

337

-821

163

278

-915

-617

-1,441

897

-918

650

-375

518

319

1,957

-433

-114

549

-344

250

-694

137

-476

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-3,863

-4,865

-3,444

-4,610

-3,490

-4,601

-5,084

-2,987

-4,311

-3,113

-3,282

-2,412

-3,619

Equity method investment in Galectin Sciences LLC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

400

Net cash from operating activities

-4,371

-3,759

-1,475

-2,330

-3,284

-2,007

-1,577

-3,079

-3,516

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash from investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

-400

CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock and warrants

219

902

163

47,401

2,003

124

1,216

9,588

4,451

-1

954

485

2,145

-

-

-

-

9,128

41

0

4,532

1,099

60

0

28,178

Net proceeds from exercise of common stock warrants and options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-59

0

241

1,946

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

2,145

-

-

-

-

9,128

41

0

4,532

1,040

60

241

30,124

Net cash from financing activities

219

902

-231

47,401

2,003

124

1,216

9,588

4,451

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NET DECREASE IN CASH AND CASH EQUIVALENTS

-4,152

-

-

-

-1,281

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NET INCREASE IN CASH AND CASH EQUIVALENTS

-

-

-

-

-

-

-

6,509

935

-3,905

-2,169

-4,517

-1,718

-697

-1,944

-4,353

-3,490

4,527

-5,043

-2,987

221

-2,073

-3,222

-2,171

26,105

NONCASH FINANCING ACTIVITIES:
Payment of preferred stock dividends in common stock

60

-

-

-

-

0

361

201

353

338

321

234

339

208

131

183

220

239

208

161

260

180

275

176

312